Figure 1. Transfer of Omalizumab and Peanut protein across the placental barrier.
(A) In the human placental ex vivo model sample in-flow (artery) and out-flow (vein) are recorded to and from the placental tissue. (B) Omalizumab and (C) peanut extract transfer kinetics as percent change from maternal artery to fetal vein detected via ELISA.
Figure 2 . Placental peanut allergen transfer in the context of plasma from allergic individual and omalizumab . (A) Ara h 2 concentrations (ng/mL) in fetal vein and artery samples were determined by ELISA in PE alone (dashed line, 1.03 ng/mL) and PE/PA compared to PE/PA/Oma experiments. (B) Basophil activation tests were conducted by flow cytometry to assess the functionality of transferred allergen. Activation levels are expressed as %CD63+ basophils in PE, PE/PA and PE/PA/Oma experiments.